Sanofi Files 6-K with Mid-Year Financial Updates
Ticker: SNYNF · Form: 6-K · Filed: Oct 27, 2025 · CIK: 1121404
| Field | Detail |
|---|---|
| Company | Sanofi (SNYNF) |
| Form Type | 6-K |
| Filed Date | Oct 27, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-statements, interim-reporting, discontinued-operations
TL;DR
Sanofi's Q2 2025 financials are in, showing Opella as discontinued. Check the 12/31/24 audited statements too.
AI Summary
Sanofi filed a 6-K on October 27, 2025, presenting unaudited condensed half-year consolidated financial statements as of June 30, 2025. These statements should be read alongside the audited financial statements for the year ended December 31, 2024. The filing notes re-presentation of 2024 figures to reflect Opella as a discontinued operation, including impacts from derecognition of non-controlling interests and issuance of restricted shares.
Why It Matters
This filing provides investors with updated financial information for Sanofi's performance through the first half of 2025, including adjustments related to discontinued operations.
Risk Assessment
Risk Level: low — This is a routine financial filing (6-K) providing updated interim financial statements, not indicating new material risks.
Key Numbers
- June 30, 2025 — Reporting Period End Date (Date of the unaudited condensed half-year consolidated financial statements)
- December 31, 2024 — Prior Audited Financial Statement Date (Reference point for comparison with current unaudited statements)
Key Players & Entities
- Sanofi (company) — Filer of the 6-K
- Opella (company) — Discontinued operation
FAQ
What is the primary purpose of this 6-K filing?
The primary purpose is to present unaudited condensed half-year consolidated financial statements as of June 30, 2025.
What is the significance of Opella in this filing?
Opella is classified as a discontinued operation, and its figures for the 2024 comparative period have been re-presented on a consistent basis.
When were Sanofi's audited consolidated financial statements filed?
Sanofi's audited consolidated financial statements as of December 31, 2024, are referenced in this filing.
What specific financial impact related to Opella is mentioned for 2025?
For 2025, the filing mentions the impact of the issuance of restricted shares to former employees of Opella subsequent to Sanofi losing control of Opella.
What is the filing date of this 6-K?
This 6-K filing was made on October 27, 2025.
Filing Stats: 251 words · 1 min read · ~1 pages · Grade level 12.5 · Accepted 2025-10-27 07:56:26
Filing Documents
- d69958d6k.htm (6-K) — 468KB
- d69958dex991.htm (EX-99.1) — 2322KB
- d69958dex992.htm (EX-99.2) — 609KB
- d69958dex993.htm (EX-99.3) — 758KB
- g69958dsp6a.jpg (GRAPHIC) — 1KB
- g69958dsp6b.jpg (GRAPHIC) — 1KB
- g69958dsp6c.jpg (GRAPHIC) — 1KB
- 0001193125-25-250744.txt ( ) — 16842KB
- sny-20250630.xsd (EX-101.SCH) — 2348KB
- d69958d6k_htm.xml (XML) — 3969KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Dated: October 27, 2025 SANOFI By: /s/ Alexandra Roger Name: Alexandra Roger Title: Head of Legal Corporate & Finance 3